Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?: Lessons from the ESPRIT study

This publication has 25 references indexed in Scilit:

• Percutaneous Coronary Intervention in the Current Era Compared With 1985–1986
  Circulation, 2000
• Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial
  The Lancet, 2000
• Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender
  Journal of the American College of Cardiology, 2000
• Better Outcome for Women Compared With Men Undergoing Coronary Revascularization
  Circulation, 1998
• Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
  New England Journal of Medicine, 1998
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
  The Lancet, 1998
• Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
  New England Journal of Medicine, 1997
• Gender Differences in Platelet GPIIb-IIIa Activation
  Thrombosis and Haemostasis, 1997
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
  Journal of the American College of Cardiology, 1988